Alpha 2.0
Login Register
» Articles » PMID: 28207803

Side Effects Induced by the Acute Levodopa Challenge in Parkinson's Disease and Atypical Parkinsonisms

Overview
Journal PLoS One
Specialties General Medicine
Science
Date 2017 Feb 17
PMID 28207803
Citations 16
Authors
Rosario Vasta
Alessandra Nicoletti
Giovanni Mostile
Valeria Dibilio
Giorgia Sciacca
Donatella Contrafatto
Calogero Edoardo Cicero
Loredana Raciti
Antonina Luca
Mario Zappia
Affiliations
Soon will be listed here.
Abstract

Introduction: Acute levodopa challenge may be performed to predict levodopa chronic responsiveness. The aim of the study was to investigate frequency of side effects during the acute levodopa challenge in PD and atypical parkinsonisms.

Methods: We enrolled 34 de novo PD patients and 29 patients affected by atypical parkinsonisms (Multiple System Atrophy, MSA, n = 10; Progressive Supranuclear Palsy, PSP, n = 12 and Corticobasal Degeneration, CBD, n = 7) who underwent an acute levodopa challenge. Side effects occurring during test were recorded.

Results: Side effects were more frequent among atypical parkinsonisms as unique group when compared to PD patients (64.3% versus 23.5%; p-value 0.002) with an adjusted OR of 4.36 (95%CI 1.40-13.5). Each atypical parkinsonisms showed almost double occurrence of side effects (MSA 90%, PSP 41.7% and CBD 57%).

Conclusions: Side effects during acute levodopa challenge may be frequent in atypical parkinsonisms. This information could be useful in order to better prepare the patient for the test. Furthermore, it could represent a useful cue in differential diagnosis with PD.

Citing Articles

Dopaminergic responsiveness and dopaminergic challenge tests of Parkinson's disease: a systematic review and meta-analysis.

Kou W, Cai H, Cui Y, Zhu J, Li S, Yang C J Neurol. 2025; 272(2):176.

PMID: 39891751 DOI: 10.1007/s00415-025-12894-8.

Acute Levodopa Challenge in Atypical Parkinsonism: Comprehensive Analysis of Individual Motor Responses.

Ye L, Sani S, Veith Sanches L, Krey L, Wegner F, Hollerhage M Brain Sci. 2024; 14(10).

PMID: 39452005 PMC: 11506334. DOI: 10.3390/brainsci14100991.

The potential of arts therapies in Parkinson's disease rehabilitation: A comprehensive review.

Li Y, Luo X, Zhang A, Ying F, Wang J, Huang G Heliyon. 2024; 10(16):e35765.

PMID: 39229526 PMC: 11369473. DOI: 10.1016/j.heliyon.2024.e35765.

[Complexity of diagnosis and treatment of neuropathic pain].

Martinez Escriva G, Lopez de Coca Perez T, Royo L Farm Comunitarios. 2024; 15(2):41-44.

PMID: 39155964 PMC: 11328699. DOI: 10.33620/FC.2173-9218.(2023).12.

Synergistic effects of lipopolysaccharide and rotenone on dopamine neuronal damage in rats.

He J, Li D, Wen Q, Qin T, Long H, Zhang S CNS Neurosci Ther. 2023; 29(8):2281-2291.

PMID: 36942519 PMC: 10352892. DOI: 10.1111/cns.14180.

References
1.
Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner W . Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006; 66(7):968-75. DOI: 10.1212/01.wnl.0000215437.80053.d0. View
2.
Quattrone A, Zappia M, Aguglia U, Branca D, Colao R, Montesanti R . The subacute levodopa test for evaluating long-duration response in Parkinson's disease. Ann Neurol. 1995; 38(3):389-95. DOI: 10.1002/ana.410380308. View
3.
Gilman S, Wenning G, Low P, Brooks D, Mathias C, Trojanowski J . Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008; 71(9):670-6. PMC: 2676993. DOI: 10.1212/01.wnl.0000324625.00404.15. View
4.
Zappia M, Montesanti R, Colao R, Branca D, Nicoletti G, Aguglia U . Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease. Mov Disord. 1997; 12(1):103-6. DOI: 10.1002/mds.870120118. View
5.
Estevez S, Perez-Lloret S, Merello M . Does clinical intolerance to a diagnostic acute levodopa challenge differentiate multiple system atrophy from PD?. Int J Neurosci. 2009; 119(12):2257-61. DOI: 10.3109/00207450903139721. View